Skip to main content

Investors

Moberg Pharma’s share is listed on the main list at NASDAQ OMX Stockholm. Moberg Pharma’s goal is to create value and provide attractive shareholder returns through the successful commercialization of its pipeline assets.

 

Aktiekurs 17 Jun 2013 14:30
33.90 kr
1.19 %

Latest report

2020-08-11 Interim report April – June 2020

Calendar/presentations

Next calendar event: 2020-11-10 Interim report for July 2019 - September 2020

Contact Investor
relations:

Anna Ljung, CEO
Tel. +46 (0)8 522 307 01
Email: anna.ljung@mobergpharma.se

Peter Wolpert, Executive Chairman and Founder
Tel: +46 (0)8 522 307 08
Email: peter.wolpert@mobergpharma.se
 

 

Subscribe

Get our latest press releases and reports